DOCSLIB.ORG

Uncovering the Mechanisms of Adenosine Receptor-Mediated Pain Control: Focus on the A3 Receptor Subtype

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Uncovering the Mechanisms of Adenosine Receptor-Mediated Pain Control: Focus on the A3 Receptor Subtype International Journal of Molecular Sciences Review Uncovering the Mechanisms of Adenosine Receptor-Mediated Pain Control: Focus on the A3 Receptor Subtype Elisabetta Coppi 1,* , Federica Cherchi 1 , Elena Lucarini 1 , Carla Ghelardini 1, Felicita Pedata 1, Kenneth A. Jacobson 2 , Lorenzo Di Cesare Mannelli 1 , Anna Maria Pugliese 1 and Daniela Salvemini 3 1 Department NEUROFARBA, Division of Pharmacology and Toxicology, University of Florence, 50139 Firenze, Italy; federica.cherchi@unifi.it (F.C.); elena.lucarini@unifi.it (E.L.); carla.ghelardini@unifi.it (C.G.); felicita.pedata@unifi.it (F.P.); lorenzo.mannelli@unifi.it (L.D.C.M.); annamaria.pugliese@unifi.it (A.M.P.) 2 Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0810, USA; [email protected] 3 Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA; [email protected] * Correspondence: elisabetta.coppi@unifi.it Abstract: Agonists of the Gi protein-coupled A3 adenosine receptor (A3AR) have shown important pain-relieving properties in preclinical settings of several pain models. Active as a monotherapy against chronic pain, A3AR agonists can also be used in combination with classic opioid analgesics. Their safe pharmacological profile, as shown by clinical trials for other pathologies, i.e., rheumatoid arthritis, psoriasis and fatty liver diseases, confers a realistic translational potential, thus encouraging Citation: Coppi, E.; Cherchi, F.; research studies on the molecular mechanisms underpinning their antinociceptive actions. A number Lucarini, E.; Ghelardini, C.; Pedata, F.; of pathways, involving central and peripheral mechanisms, have been proposed. Recent evidence Jacobson, K.A.; Di Cesare Mannelli, showed that the prototypical A3AR agonist Cl-IB-MECA and the new, highly selective, A3AR agonist L.; Pugliese, A.M.; Salvemini, D. MRS5980 inhibit neuronal (N-type) voltage-dependent Ca2+ currents in dorsal root ganglia, a known Uncovering the Mechanisms of pain-related mechanism. Other proposed pathways involve reduced cytokine production, immune Adenosine Receptor-Mediated Pain cell-mediated responses, as well as reduced microglia and astrocyte activation in the spinal cord. The Control: Focus on the A3 Receptor aim of this review is to summarize up-to-date information on A3AR in the context of pain, including Subtype. Int. J. Mol. Sci. 2021, 22, cellular and molecular mechanisms underlying this effect. Based on their safety profile shown in 7952. https://doi.org/10.3390/ ijms22157952 clinical trials for other pathologies, A3AR agonists are proposed as novel, promising non-narcotic agents for pain control. Academic Editor: Cristina Missale Keywords: A3 adenosine receptor; neuropathic pain; visceral pain; dorsal root ganglion neurons; Received: 5 July 2021 Ca2+ currents; T cells; interleukin-10; adenosine Accepted: 20 July 2021 Published: 26 July 2021 Publisher’s Note: MDPI stays neutral 1. Introduction with regard to jurisdictional claims in Chronic pain is a highly debilitating condition, disturbing all aspects of our daily published maps and institutional affil- experience in social and career-related contexts. The pharmacological tools currently iations. available are sometimes inadequate, or, as in the case of opioids, limited by serious adverse effects [1]. Thus, efforts are being made to pursue research into innovative, non-opioid, pain-relieving compounds. Many experimental reports have identified adenosine receptors (ARs) as potential Copyright: © 2021 by the authors. targets for acute or chronic pain management. Adenosine is a ubiquitous endogenous Licensee MDPI, Basel, Switzerland. neuromodulator whose actions are mediated by four G protein-coupled receptors (GPCR), This article is an open access article namely A1,A2A,A2B and A3 receptors (A1Rs, A2ARs, A2BRs and A3Rs). A1Rs and A3Rs distributed under the terms and are coupled to Gi members of the G protein family, while A2ARs and A2BRs are Gs-coupled conditions of the Creative Commons receptors [2]. The consequent modulation of cyclic adenosine monophosphate (cAMP) Attribution (CC BY) license (https:// levels activates or inhibits a number of signaling pathways, depending on the specific type creativecommons.org/licenses/by/ of cell involved (Figure1). In some cases, A 2BR might also couple to Gq proteins, as well as 4.0/). Int. J. Mol. Sci. 2021, 22, 7952. https://doi.org/10.3390/ijms22157952 https://www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 2 of 13 Int. J. Mol. Sci. 2021, 22, 7952 2 of 13 (cAMP) levels activates or inhibits a number of signaling pathways, depending on the specific type of cell involved (Figure 1). In some cases, A2BR might also couple to Gq pro- teins,A1Rs as to thewell G aso protein.A1Rs to Allthe ARsGo protein. are coupled All ARs to mitogen-activatedare coupled to mitogen-activated protein kinase(MAPK) protein kinasepathways, (MAPK) including pathways, extracellular including signal-regulated extracellular signal-regulated kinase 1/2 (ERK1/2), kinase p38 1/2 MAPK (ERK1/2), and p38Jc-Jun-NH2 MAPK and terminal Jc-Jun-NH2 Kinase terminal (JNK) [3 ].Kinase (JNK) [3]. FigureFigure 1. AdenosineAdenosine receptors receptors and and the the main main transduction transduction pathways pathways involved involved in in their their activation. activation. SchematicSchematic representation ofof GG protein-coupledprotein-coupled A A1,A1, A2A2A,A, A2B2B andand AA33 receptorreceptor (A(A11R,R, AA2A2AR, A2BRR and AA33R)R) subtypes subtypes activated activated by by extracellular extracellular adenosine adenosine (ADO), (ADO), and and the the main main intracellular intracellular pathways pathways in- volved. A2ARs and A2BRs are coupled to the Gs protein, which leads to adenylyl cyclase (AC) acti- involved. A2ARs and A2BRs are coupled to the Gs protein, which leads to adenylyl cyclase (AC) vation and cyclic AMP (cAMP) increase. On the other hand, A1R and A3R are coupled to the Gi activation and cyclic AMP (cAMP) increase. On the other hand, A1R and A3R are coupled to the protein that inhibits AC and reduces cAMP. In some districts, A2BRs are also coupled with Gq pro- Gi protein that inhibits AC and reduces cAMP. In some districts, A2BRs are also coupled with Gq teins and A1R with Go, which stimulate Ca2+ release from intracellular stores. All adenosine recep- proteins and A R with Go, which stimulate Ca2+ release from intracellular stores. All adenosine tors are coupled1 to mitogen-activated protein kinase (MAPK) pathways, including extracellular sig- nal-regulatedreceptors are coupledkinase 1/2 to mitogen-activated(ERK1/2), p38 MAPK protein and kinaseJc-Jun-NH2 (MAPK) terminal pathways, Kinase including (JNK). extracellular signal-regulated kinase 1/2 (ERK1/2), p38 MAPK and Jc-Jun-NH2 terminal Kinase (JNK). A variety of functions are regulated by purines: cardiovascular, respiratory, inflam- A variety of functions are regulated by purines: cardiovascular, respiratory, inflam- matory and immune events [4–6], as well as neuronal maturation [7,8] and hypoxic dam- matory and immune events [4–6], as well as neuronal maturation [7,8] and hypoxic dam- age [9,10]. Of note, adenosine receptors are expressed within the pain-related areas in the age [9,10]. Of note, adenosine receptors are expressed within the pain-related areas in the peripheral or central nervous system (CNS). It is known that ARs are widely distributed peripheral or central nervous system (CNS). It is known that ARs are widely distributed on on neurons and glia; hence, considerable interest is focused on the development of selec- neurons and glia; hence, considerable interest is focused on the development of selective tive AR ligands able to control neurological alterations in nervous system diseases [11– AR ligands able to control neurological alterations in nervous system diseases [11–14]. 14]. Importantly, local levels of adenosine are significantly enhanced during events of tis- Importantly, local levels of adenosine are significantly enhanced during events of tissue sue inflammation, stress or trauma, as well as during hypoxia-ischemia [15,16]. Adenosine inflammation, stress or trauma, as well as during hypoxia-ischemia [15,16]. Adenosine is a is a potent anti-inflammatory autacoid that inhibits a number of inflammatory mecha- potent anti-inflammatory autacoid that inhibits a number of inflammatory mechanisms, nisms,including including phagocytosis, phagocytosis, the generation the generation of toxic of oxygen toxic metabolites,oxygen metabolites, cytokine cytokine release and re- leasecellular and adhesion cellular [adhesion17]. Most [17]. of these Most anti-inflammatory of these anti-inflammatory effects were effects first ascribed were first to theas- cribed to the activation of “A2Rs” [18], before further investigation attributed the anti- activation of “A2Rs” [18], before further investigation attributed the anti-inflammatory inflammatory effect of adenosine to A2ARs [19], which are widely expressed on peripheral effect of adenosine to A2ARs [19], which are widely expressed on peripheral blood and bloodimmune and cells immune [20]. cells [20]. MovingMoving in moremore detaildetail to to pain pain transmission, transmission, the the first first proof proof of adenosine’sof adenosine’s involvement involve- mentin anti-nociception in anti-nociception dates dates from from the 1970s, the 1970s, when when the systemic
Load more

Recommended publications
  • Purinergic Signalling in Skin
    PURINERGIC SIGNALLING IN SKIN AINA VH GREIG MA FRCS Autonomic Neuroscience Institute Royal Free and University College School of Medicine Rowland Hill Street Hampstead London NW3 2PF in the Department of Anatomy and Developmental Biology University College London Gower Street London WCIE 6BT 2002 Thesis Submitted for the Degree of Doctor of Philosophy University of London ProQuest Number: U643205 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest U643205 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 ABSTRACT Purinergic receptors, which bind ATP, are expressed on human cutaneous kératinocytes. Previous work in rat epidermis suggested functional roles of purinergic receptors in the regulation of proliferation, differentiation and apoptosis, for example P2X5 receptors were expressed on kératinocytes undergoing proliferation and differentiation, while P2X? receptors were associated with apoptosis. In this thesis, the aim was to investigate the expression of purinergic receptors in human normal and pathological skin, where the balance between these processes is changed. A study was made of the expression of purinergic receptor subtypes in human adult and fetal skin.
    [Show full text]
  • P2Y Purinergic Receptors, Endothelial Dysfunction, and Cardiovascular Diseases
    International Journal of Molecular Sciences Review P2Y Purinergic Receptors, Endothelial Dysfunction, and Cardiovascular Diseases Derek Strassheim 1, Alexander Verin 2, Robert Batori 2 , Hala Nijmeh 3, Nana Burns 1, Anita Kovacs-Kasa 2, Nagavedi S. Umapathy 4, Janavi Kotamarthi 5, Yash S. Gokhale 5, Vijaya Karoor 1, Kurt R. Stenmark 1,3 and Evgenia Gerasimovskaya 1,3,* 1 The Department of Medicine Cardiovascular and Pulmonary Research Laboratory, University of Colorado Denver, Aurora, CO 80045, USA; [email protected] (D.S.); [email protected] (N.B.); [email protected] (V.K.); [email protected] (K.R.S.) 2 Vascular Biology Center, Augusta University, Augusta, GA 30912, USA; [email protected] (A.V.); [email protected] (R.B.); [email protected] (A.K.-K.) 3 The Department of Pediatrics, Division of Critical Care Medicine, University of Colorado Denver, Aurora, CO 80045, USA; [email protected] 4 Center for Blood Disorders, Augusta University, Augusta, GA 30912, USA; [email protected] 5 The Department of BioMedical Engineering, University of Wisconsin, Madison, WI 53706, USA; [email protected] (J.K.); [email protected] (Y.S.G.) * Correspondence: [email protected]; Tel.: +1-303-724-5614 Received: 25 August 2020; Accepted: 15 September 2020; Published: 18 September 2020 Abstract: Purinergic G-protein-coupled receptors are ancient and the most abundant group of G-protein-coupled receptors (GPCRs). The wide distribution of purinergic receptors in the cardiovascular system, together with the expression of multiple receptor subtypes in endothelial cells (ECs) and other vascular cells demonstrates the physiological importance of the purinergic signaling system in the regulation of the cardiovascular system.
    [Show full text]
  • Hypoxia Modulates Platelet Purinergic Signalling Pathways
    Published online: 2019-12-13 THIEME Cellular Haemostasis and Platelets 253 Hypoxia Modulates Platelet Purinergic Signalling Pathways Gordon G. Paterson1,2 Jason M. Young1,2 Joseph A. Willson3 Christopher J. Graham1,2 Rebecca C. Dru1,2 Eleanor W. Lee1,2 Greig S. Torpey1,2 Sarah R. Walmsley3 Melissa V. Chan4 Timothy D. Warner4 John Kenneth Baillie1,5,6 Alfred Arthur Roger Thompson1,7 1 APEX (Altitude Physiology Expeditions), Edinburgh, United Kingdom Address for correspondence Alfred Arthur Roger Thompson, BSc, MB 2 Edinburgh Medical School, University of Edinburgh, Edinburgh, ChB,MRCP,PhD,DepartmentofInfection,Immunityand United Kingdom Cardiovascular Disease, University of Sheffield, M127a, Royal 3 University of Edinburgh Centre for Inflammation Research, The Hallamshire Hospital, Beech Hill Road, Sheffield S10 2RX, Queen’s Medical Research Institute, University of Edinburgh, United Kingdom (e-mail: R.Thompson@sheffield.ac.uk). Edinburgh, United Kingdom 4 Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom 5 Division of Genetics and Genomics, The Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom 6 Department of Anaesthesia, Critical Care and Pain Medicine, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, United Kingdom 7 Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom Thromb Haemost 2020;120:253–261. Abstract Background Hypoxia resulting from ascent to high-altitude or pathological states at sea level is known to increase platelet reactivity. Previous work from our group has suggested that this may be adenosine diphosphate (ADP)-specific. Given the clinical importance of drugs targeting ADP pathways, research into the impact of hypoxia on platelet ADP pathways is highly important.
    [Show full text]
  • Adenosine Receptors and Cancer
    Adenosine Receptors and Cancer P. Fishman, S. Bar-Yehuda, M. Synowitz, J.D. Powell, K.N. Klotz, S. Gessi, and P.A. Borea Contents 1 Introduction..................................................................................... 402 2A1 Adenosine Receptor........................................................................ 402 3A2A Adenosine Receptor...................................................................... 406 3.1 The A2AAR:ProtectorofHostTissue,ProtectorofTumors......................... 406 3.2 TumorsEvadetheImmuneSystembyInhibitingImmuneCellFunction........... 406 3.3 The A2AAR Negatively Regulates Immune Responses............................... 407 3.4 AdenosineProtectsTumorsfromImmuneDestruction............................... 408 3.5 A2AAR Antagonism as a Means of Enhancing Immunotherapy..................... 410 4A2B Adenosine Receptors..................................................................... 410 5A3 Adenosine Receptor........................................................................ 414 5.1 Overexpression of the A3AR in Tumor Versus Normal Adjacent Tissues........... 415 5.2 InVitroStudies......................................................................... 417 5.3 InVivoStudies.......................................................................... 419 5.4 Mechanisms of Action for the Anticancer Activity of the A3AR.................... 424 6 Anticancer Activity of A3AR Antagonists.................................................... 429 7 SummaryandConclusions...................................................................
    [Show full text]
  • Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?
    cells Review Alzheimer and Purinergic Signaling: Just a Matter of Inflammation? Stefania Merighi 1, Tino Emanuele Poloni 2, Anna Terrazzan 1, Eva Moretti 1, Stefania Gessi 1,* and Davide Ferrari 3,* 1 Department of Translational Medicine and for Romagna, University of Ferrara, 44100 Ferrara, Italy; [email protected] (S.M.); [email protected] (A.T.); [email protected] (E.M.) 2 Department of Neurology and Neuropathology, Golgi-Cenci Foundation & ASP Golgi-Redaelli, Abbiategrasso, 20081 Milan, Italy; [email protected] 3 Department of Life Science and Biotechnology, University of Ferrara, 44100 Ferrara, Italy * Correspondence: [email protected] (S.G.); [email protected] (D.F.) Abstract: Alzheimer’s disease (AD) is a widespread neurodegenerative pathology responsible for about 70% of all cases of dementia. Adenosine is an endogenous nucleoside that affects neurode- generation by activating four membrane G protein-coupled receptor subtypes, namely P1 receptors. One of them, the A2A subtype, is particularly expressed in the brain at the striatal and hippocampal levels and appears as the most promising target to counteract neurological damage and adenosine- dependent neuroinflammation. Extracellular nucleotides (ATP, ADP, UTP, UDP, etc.) are also released from the cell or are synthesized extracellularly. They activate P2X and P2Y membrane receptors, eliciting a variety of physiological but also pathological responses. Among the latter, the chronic inflammation underlying AD is mainly caused by the P2X7 receptor subtype. In this review we offer an overview of the scientific evidence linking P1 and P2 mediated purinergic signaling to AD devel- opment. We will also discuss potential strategies to exploit this knowledge for drug development.
    [Show full text]
  • A3 Adenosine Receptor As a Target for Cancer Therapy
    Anti-Cancer Drugs 2002, 13, pp. 437-443 Review paper A3 adenosine receptor as a target for cancer therapy Pnina Fishman,1,2 Sara Bar-Yehuda,1 Lea Madi2 and Ilan Cohn2 1Laboratory of Clinical and Tumor Immunology,The Felsenstein Medical Research Center,Tel-Aviv University, Rabin Medical Center, Petach Tikva 49100, Israel. 2Can-Fite BioPharma, Kiryat-Matalon, Petach Tikva 49160, Israel. Targeting the A3 adenosine receptor (A3AR) by adenosine or a tumor metastases are extremely rare in muscle tissue, synthetic agonist to this receptor (IB-MECA and Cl-IB-MECA) not withstanding the fact that it constitutes about results in a di¡erential e¡ect on tumor and on normal cells. Both the adenosine and the agonists inhibit the growth of various tumor 65–70% of lean body mass. This observation led to cell types such as melanoma, colon or prostate carcinoma and research that has its purpose to decipher the lymphoma. This e¡ect is speci¢c and is exerted on tumor cells physiological basis for this intruiging phenomenon. only. Moreover, exposure of peripheral blood mononuclear cells It was found that muscle cells secrete small mole- to adenosine or the agonists leads to the induction of granulocyte cules (MF) which inhibit growth of tumor cells.1,2 colony stimulating factor (G-CSF) production.When given orally to mice, the agonists suppress the growth of melanoma, colon and This growth inhibitory effect was observed on a prostate carcinoma in these animals, while inducing a myelopro- broad range of different tumor cell lines in vitro, tective e¡ect via the induction of G-CSF production.The de-regu- such as melanoma, carcinoma, leukomia and lym- lation of theWnt signaling pathway was found to be involved in the phoma.
    [Show full text]
  • Caffeine Has a Dual Influence on NMDA Receptor–Mediated Glutamatergic Transmission at the Hippocampus
    Purinergic Signalling https://doi.org/10.1007/s11302-020-09724-z ORIGINAL ARTICLE Caffeine has a dual influence on NMDA receptor–mediated glutamatergic transmission at the hippocampus Robertta S. Martins1,2 & Diogo M. Rombo1,3 & Joana Gonçalves-Ribeiro1,3 & Carlos Meneses4 & Vladimir P. P. Borges-Martins2 & Joaquim A. Ribeiro1,3 & Sandra H. Vaz1,3 & Regina C. C. Kubrusly2 & Ana M. Sebastião1,3 Received: 19 June 2020 /Accepted: 20 August 2020 # Springer Nature B.V. 2020 Abstract Caffeine, a stimulant largely consumed around the world, is a non-selective adenosine receptor antagonist, and therefore caffeine actions at synapses usually, but not always, mirror those of adenosine. Importantly, different adenosine receptors with opposing regulatory actions co-exist at synapses. Through both inhibitory and excitatory high-affinity receptors (A1RandA2R, respec- tively), adenosine affects NMDA receptor (NMDAR) function at the hippocampus, but surprisingly, there is a lack of knowledge on the effects of caffeine upon this ionotropic glutamatergic receptor deeply involved in both positive (plasticity) and negative (excitotoxicity) synaptic actions. We thus aimed to elucidate the effects of caffeine upon NMDAR-mediated excitatory post- synaptic currents (NMDAR-EPSCs), and its implications upon neuronal Ca2+ homeostasis. We found that caffeine (30–200 μM) facilitates NMDAR-EPSCs on pyramidal CA1 neurons from Balbc/ByJ male mice, an action mimicked, as well as occluded, by 1,3-dipropyl-cyclopentylxantine (DPCPX, 50 nM), thus likely mediated by blockade of inhibitory A1Rs. This action of caffeine cannot be attributed to a pre-synaptic facilitation of transmission because caffeine even increased paired-pulse facilitation of NMDA-EPSCs, indicative of an inhibition of neurotransmitter release.
    [Show full text]
  • Biased Signaling of G Protein Coupled Receptors (Gpcrs): Molecular Determinants of GPCR/Transducer Selectivity and Therapeutic Potential
    Pharmacology & Therapeutics 200 (2019) 148–178 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR/transducer selectivity and therapeutic potential Mohammad Seyedabadi a,b, Mohammad Hossein Ghahremani c, Paul R. Albert d,⁎ a Department of Pharmacology, School of Medicine, Bushehr University of Medical Sciences, Iran b Education Development Center, Bushehr University of Medical Sciences, Iran c Department of Toxicology–Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Iran d Ottawa Hospital Research Institute, Neuroscience, University of Ottawa, Canada article info abstract Available online 8 May 2019 G protein coupled receptors (GPCRs) convey signals across membranes via interaction with G proteins. Origi- nally, an individual GPCR was thought to signal through one G protein family, comprising cognate G proteins Keywords: that mediate canonical receptor signaling. However, several deviations from canonical signaling pathways for GPCR GPCRs have been described. It is now clear that GPCRs can engage with multiple G proteins and the line between Gprotein cognate and non-cognate signaling is increasingly blurred. Furthermore, GPCRs couple to non-G protein trans- β-arrestin ducers, including β-arrestins or other scaffold proteins, to initiate additional signaling cascades. Selectivity Biased Signaling Receptor/transducer selectivity is dictated by agonist-induced receptor conformations as well as by collateral fac- Therapeutic Potential tors. In particular, ligands stabilize distinct receptor conformations to preferentially activate certain pathways, designated ‘biased signaling’. In this regard, receptor sequence alignment and mutagenesis have helped to iden- tify key receptor domains for receptor/transducer specificity.
    [Show full text]
  • Regulation of Microglial Functions by Purinergic Mechanisms in the Healthy and Diseased CNS
    cells Review Regulation of Microglial Functions by Purinergic Mechanisms in the Healthy and Diseased CNS Peter Illes 1,2,*, Patrizia Rubini 2, Henning Ulrich 3, Yafei Zhao 4 and Yong Tang 2,4 1 Rudolf Boehm Institute for Pharmacology and Toxicology, University of Leipzig, 04107 Leipzig, Germany 2 International Collaborative Centre on Big Science Plan for Purine Signalling, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China; [email protected] (P.R.); [email protected] (Y.T.) 3 Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo 748, Brazil; [email protected] 4 Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China; [email protected] * Correspondence: [email protected]; Tel.: +49-34-1972-46-14 Received: 17 March 2020; Accepted: 27 April 2020; Published: 29 April 2020 Abstract: Microglial cells, the resident macrophages of the central nervous system (CNS), exist in a process-bearing, ramified/surveying phenotype under resting conditions. Upon activation by cell-damaging factors, they get transformed into an amoeboid phenotype releasing various cell products including pro-inflammatory cytokines, chemokines, proteases, reactive oxygen/nitrogen species, and the excytotoxic ATP and glutamate. In addition, they engulf pathogenic bacteria or cell debris and phagocytose them. However, already resting/surveying microglia have a number of important physiological functions in the CNS; for example, they shield small disruptions of the blood–brain barrier by their processes, dynamically interact with synaptic structures, and clear surplus synapses during development. In neurodegenerative illnesses, they aggravate the original disease by a microglia-based compulsory neuroinflammatory reaction.
    [Show full text]
  • Purinergic Receptors Brian F
    Chapter 21 Purinergic receptors Brian F. King and Geoffrey Burnstock 21.1 Introduction The term purinergic receptor (or purinoceptor) was first introduced to describe classes of membrane receptors that, when activated by either neurally released ATP (P2 purinoceptor) or its breakdown product adenosine (P1 purinoceptor), mediated relaxation of gut smooth muscle (Burnstock 1972, 1978). P2 purinoceptors were further divided into five broad phenotypes (P2X, P2Y, P2Z, P2U, and P2T) according to pharmacological profile and tissue distribution (Burnstock and Kennedy 1985; Gordon 1986; O’Connor et al. 1991; Dubyak 1991). Thereafter, they were reorganized into families of metabotropic ATP receptors (P2Y, P2U, and P2T) and ionotropic ATP receptors (P2X and P2Z) (Dubyak and El-Moatassim 1993), later redefined as extended P2Y and P2X families (Abbracchio and Burnstock 1994). In the early 1990s, cDNAs were isolated for three heptahelical proteins—called P2Y1, P2Y2, and P2Y3—with structural similarities to the rhodopsin GPCR template. At first, these three GPCRs were believed to correspond to the P2Y, P2U, and P2T receptors. However, the com- plexity of the P2Y receptor family was underestimated. At least 15, possibly 16, heptahelical proteins have been associated with the P2Y receptor family (King et al. 2001, see Table 21.1). Multiple expression of P2Y receptors is considered the norm in all tissues (Ralevic and Burnstock 1998) and mixtures of P2 purinoceptors have been reported in central neurones (Chessell et al. 1997) and glia (King et al. 1996). The situation is compounded by P2Y protein dimerization to generate receptor assemblies with subtly distinct pharmacological proper- ties from their constituent components (Filippov et al.
    [Show full text]
  • Special Issue for Purinergic Receptors, Particularly P2X7 Receptor, in the Eye
    vision Editorial Special Issue for Purinergic Receptors, Particularly P2X7 Receptor, in the Eye Tetsuya Sugiyama 1,2,3 1 Nakano Eye Clinic of Kyoto Medical Co-operative, Kyoto 604-8404, Japan; [email protected]; Tel.: +81-75-801-4151 2 Department of Ophthalmology, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan 3 Department of Ophthalmology, Toho University Sakura Medical Center, Sakura, Chiba 285-8741, Japan Received: 23 July 2018; Accepted: 23 July 2018; Published: 24 July 2018 Purinergic receptors, also known as purinoceptors, are a family of plasma membrane molecules found in almost all mammalian tissues [1]. In the field of purinergic signaling, these receptors play a role in many physiological functions, such as learning, memory, locomotion, and sleep [2]. Specifically, they are involved in several cellular functions including proliferation and migration of neural stem cells, vascular reactivity, apoptosis, and cytokine secretion [2,3]. The term ‘purinergic receptor’ was originally introduced to describe specific classes of membrane receptors that mediate relaxation of gastrointestinal smooth muscle as a response to the release of ATP—adenosine triphosphate (P2 receptors) or adenosine (P1 receptors). P2 receptors have been further divided into two subclasses: P2X and P2Y [4]. P2X receptors are a family of ligand-gated ion channels that allow the passage of ions across cell membranes. P2Y receptors are a family of G-protein-coupled receptors that initiate an intracellular chain of reactions. Some purinergic receptors have been found to play important roles in ocular tissues including the lacrimal gland, the cornea, the trabecular meshwork, the lens, and the retina [5].
    [Show full text]
  • Purinergic Signalling in Neurodegeneration, Neuroprotection and Neuroregeneration
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery [Special Issue of Neuropharmacology entitled ‘Purines in Neurodegeneration and Neuroregeneration’. Guest Editors: Peter Illes, Alex Verkhratsky, Beata Sperlágh and Geoff Burnstock] An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration By Geoffrey Burnstock Autonomic Neuroscience Centre, University College Medical School, Rowland Hill Street, London NW3 2PF, UK. And Department of Pharmacology and Therapeutics, The University of Melbourne, Australia E-mail: [email protected] Tel: +44 20 7830 2948 Fax: +44 20 7830 2949 1 Introduction Trauma, ischaemia and stroke Neurodegenerative diseases Alzheimer's disease Parkinson's disease Huntington's disease Multiple sclerosis Amyotrophic lateral sclerosis Neuroprotection Neuroprotection against trauma, ischaemia and stroke Neuroprotection against neurodegenerative diseases Neuroregeneration: neural stem/progenitor cells Conclusions Abstract Purinergic signalling appears to play important roles in neurodegeneration, neuroprotection and neuroregeneration. Initially there is a brief summary of the background of purinergic signalling, including release of purines and pyrimidines from neural and non-neural cells and their ectoenzymatic degradation, and the current characterisation of P1 (adenosine), and P2X (ion channel) and P2Y (G protein-coupled) nucleotide receptor subtypes. There is also coverage of the localization and roles of purinoceptors in the healthy central nervous system. The focus is then on the roles of purinergic signalling in trauma, ischaemia, stroke and in neurodegenerative diseases, including Alzheimer’s, Parkinson’s and Huntington’s diseases, as well as multiple sclerosis and amyotrophic lateral sclerosis. Neuroprotective mechanisms involving purinergic signalling are considered and its involvement in neuroregeneration, including the role of adult neural stem/progenitor cells.
    [Show full text]